Five things for pharma marketers to know: Monday, October 20, 2014

Five things for pharma marketers to know: Monday, October 20, 2014

Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."

The importance of vaccine perceptions in self-pay markets

The importance of vaccine perceptions in self-pay markets

Perceptions of vaccines impact consumers' purchasing decisions

Five things for pharma marketers to know: Friday, October 17

Five things for pharma marketers to know: Friday, October 17

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

AbbVie-free Shire could open new opportunities

AbbVie-free Shire could open new opportunities

AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

Panel seems to like Novartis drug

Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.

New FDA division launches Jan. 1

Resignations stymied the Office of Pharmaceutical Quality's beginning.

Mucinex gets a revamp

Mucinex gets a revamp

After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.

Five things for pharma marketers to know: Thursday, October 16

Five things for pharma marketers to know: Thursday, October 16

AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung disease.

AbbVie reconsiders Shire

AbbVie reconsiders Shire

AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.

J&J offers government payer hep. C guarantee

The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.

New exclusivity rules confound

A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.

Cosmo moves to Ireland

Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.

Five things for pharma marketers to know: Wednesday, October 15

Five things for pharma marketers to know: Wednesday, October 15

AbbVie's board to reconsider Shire move; docs warm up to ACA; Eisai orphan thyroid cancer drug receives Priority Review.

Is your health app tourist or local?

Is your health app tourist or local?

Health apps become multilingual

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Pfizer gets palbo review date

Pfizer gets palbo review date

The FDA will vote for or against the breast cancer drug by April 13, 2015.

New Ireland tax rule does not fluster pharma

Ireland plans on closing off a tax advantage but pharma does not appear to flinch.

Five things for pharma marketers to know: Tuesday, October 14

Five things for pharma marketers to know: Tuesday, October 14

BMS, Janssen and Pharmacyclics to test Opdivo/Imbruvica pairing; Google's latest health experiment will connect docs and patients over video-conferencing Hangouts tool; Five Ranbaxy execs resign after generics firm was acquired by Sun.

FDA approves Sovaldi HCV combo

FDA approves Sovaldi HCV combo

The sofosbuvir-ledipasvir combo is expected to run the average genotype 1 patient $80,000.

Five things for pharma marketers to know: Friday, October 10

Five things for pharma marketers to know: Friday, October 10

FDA commissioner Hamburg says agency wants to hasten medical device approvals; Amgen nets priority review for Phase-II leukemia drug; Novartis employee pleads guilty to bribery allegations.

Specialty prescription costs hurt across the board

Specialty prescription costs hurt across the board

Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.

Shire delays ADD medication submission

The company is working with the FDA on new clinical trial requirements.

Mixed reaction to a health-centric Facebook feature

Mixed reaction to a health-centric Facebook feature

The ACLU is among those questioning the positives of the rumored healthcare effort.

Five things for pharma marketers to know: Thursday, October 9

Five things for pharma marketers to know: Thursday, October 9

Endo to acquire Auxilium for an estimated $2.6bn; Novartis says good-bye to three execs; NIH opens wallet for rare disease research; CMS's Open Payments show financial disparity between men and women; Clarient and GSK collaborate in cancer testing.

Cadient acquired by tech co. Cognizant

Cadient acquired by tech co. Cognizant

In an estimated $30-million deal, Pennsylvania healthcare comms agency Cadient Group is to be acquired by tech consultancy Cognizant.

Amgen releases Humira biosimilar data

The company says ABP 510 hit its primary endpoint in an adalimumab comparison.

Researchers link prescriptions and time of day

In short: more antibotic prescriptions are written in the afternoon than in the morning.

Task Force endorses T2D screening

The US Preventive Services Task Force wants adults at risk for type 2 diabetes to get tested.

Five things for pharma marketers to know: Wednesday, October 8

Five things for pharma marketers to know: Wednesday, October 8

Cadient is being acquired by consultancy Cognizant; Valeant ups the ante in Allergan bid; BMS settles Sustiva patent suits; Americans are dying at a lesser rate; Stricter Ebola screening at aiprorts.

Cardiology groups endorse AZ's Brilinta over Plavix

Two cardiology associations advise prescribing Brilinta over Plavix for management of acute chest pain without electrocardiogram changes.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

The drugmaker is poised to cut 14 pipeline projects loose.

Ogilvy CommonHealth acquires Element Marketing Group

The acquisition is meant to bolster the WPP agency's payer and market-access capabilities.

Nearly half of consumers wary of healthcare costs, insurer finds

Nearly half of consumers wary of healthcare costs, insurer finds

Cigna said found paying for medications and hospitalizations were top healthcare concerns.

Five things for pharma marketers to know: Tuesday, October 7

Five things for pharma marketers to know: Tuesday, October 7

Pfizer settles Chantix litigation; BMS scales back HCV efforts; FDA defends Zohydro approval.

PAs, NPs eager for pharma-backed patient resources: study

PAs, NPs eager for pharma-backed patient resources: study

Recent research suggests nurse practitioners and physicians assistants have a growing appetite for digital patient resources from industry.

Hospital backlash begins after Genentech imposes change

Genentech's decision to pare access to three breast cancer drugs has spurred hospitals to take action.

Analysts see potential in Novartis's serelaxin

Analysts see potential in Novartis's serelaxin

Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.

Becton Dickinson buys CareFusion

An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.

Facebook contemplates healthcare foray

Facebook contemplates healthcare foray

Sources indicate Facebook is looking to dive into the social healthcare space.

Five things for pharma marketers to know: Monday, October 6

Five things for pharma marketers to know: Monday, October 6

Novartis BMS collaboration to evaluate Opdivo paired with three lung cancer treatments; Forbes weighs in on 60 Minutes segment; Sanofi management disagreements delay established drug portfolio sale; FDA sets price for Rare Pediatric Disease Priority Review vouchers; the GPhA challenges lawmakers' misconceptions of generic drug prices.

Using performance-based pricing to tap gold in mature products

Using performance-based pricing to tap gold in mature products

The pharmaceutical industry's need for promotional spending has never been greater

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Apple Watch and Health: This Time Will Be Different

Apple Watch and Health: This Time Will Be Different

Apple's official entry into the health wearables market indicates they've taken on a considerable, new design challenge: health behavior change.

Lilly drops lupus drug from trials

Lilly drops lupus drug from trials

Eli Lilly said it discontinued tabalumab, a drug being tested in Phase-III trials for lupus, after it failed to outperform the standard of care.

Five things for pharma marketers to know: Thursday, October 2

Five things for pharma marketers to know: Thursday, October 2

Government, charities spur production of Ebola treatment Zmapp; Venture capital likes digital health this year; Eli Lilly abandons lupus drug after disappointing Phase-III trial.

Sales rep restrictions point to need for a pharma rethink

Sales rep restrictions point to need for a pharma rethink

A survey shows sales rep bans are accelerating, while also pointing to a limited-time opportunity for pharma to become a significant partner for healthcare systems.

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Five things for pharma marketers to know: Wednesday, October 1

Five things for pharma marketers to know: Wednesday, October 1

Ebola lands in the US; CMS's Open Payments database shows docs received $3.5 billion in last five months of 2013; Endo pays over $400 million to settle vaginal mesh suits.

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.

Know your audience, every member of it

Know your audience, every member of it

Give the cool 20% of your audience cool stuff, like apps. Relate to the other 80% in ways that are less cool

In an online world, don't forget the offliners

In an online world, don't forget the offliners

A level of trust happens when you have an in-person relationship that just can't be recreated online

Has risk information run rampant?

In an era when many patients prefer a conversation over a commercial, and as the FDA considers revisions to the "brief summary," how much risk information is necessary in DTC ads and why?

A court battle to crack "use codes"

A court battle to crack "use codes"

Hospira is taking to the courts to fight off generic threats to its hospital sedation drug Precedex

Upward Move: Ben Ingersoll

Upward Move: Ben Ingersoll

Ben Ingersoll, Chief creative officer, ghg

At Work With: Meredith Mae Roberts

At Work With: Meredith Mae Roberts

Meredith Mae Roberts, Senior Copywriter, HCB Health

Washington Insider : Science, Not Ideology

Washington Insider : Science, Not Ideology

A charge of sexism against the FDA clouds the views surrounding a drug's application

DDR on DTC: Biotene

DDR on DTC: Biotene

Sometimes an OTC brand looks like a DTC brand—and sometimes an OTC brand helps patients using DTC brands. This is the case with GSK's Biotene.

Down... but not out

Down... but not out

Satisfaction levels among pharma-based respondents fell, but didn't exactly tank

Sucampo goes all-in on Amitiza with new DTC effort

Sucampo goes all-in on Amitiza with new DTC effort

The drugmaker is debuting a DTC campaign for the older constipation drug, despite a crowded therapeutic category and potential generics on the horizon.

Payers OK-ish with orphan drug prices

A survey shows fewer payers expect more restrictive policies in the near-term.

American Academy of Neurology releases opioid policy

The reveal comes days before hydrocodone products jump to a more restrictive access tier.

Five things for pharma marketers to know: Tuesday, September 30

Five things for pharma marketers to know: Tuesday, September 30

New Pfizer Viagra ads bring women into limelight; Open Payments database debuts to criticism; AbbVie/Shire deal set to be completed.

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

Late-stage immunotherapy results presented at a European medical conference over the weekend were heralded by clinicians, as AstraZeneca's lung-cancer darkhorse showcased strong early-stage results.

Pacira gets OPDP opioid promotion Warning Letter

Pacira gets OPDP opioid promotion Warning Letter

The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Consumers modify mobile health devices

Mobile health devices may be more than they appear to be—consumers are taking an open-source approach to getting the monitors they want.

Five things for Pharma Marketers to know: Monday, September 29

Five things for Pharma Marketers to know: Monday, September 29

Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.

Five things for pharma marketers to know: Friday, September 26

Five things for pharma marketers to know: Friday, September 26

US government looks for alternative, nondrug, pain relief options for veterans; Gilead's HCV combo scores positive opinion in EU; FDA reopens commentary for social media draft guidance.

How the New Marketplace Will Affect Drug Access

How the New Marketplace Will Affect Drug Access

There are similarities between the 2014 formularies and their commercial counterparts. However, differences in the drug benefit designs show the predominance of four to five tiers, higher deductibles and higher copays or coinsurance levels compared to commercial benefits.

Five things for pharma marketers to know: Thursday, September 25

Five things for pharma marketers to know: Thursday, September 25

Shire pays $56-million fine to resolve improper ADHD marketing claims; FDA updates Chantix labeling to reflect new safety studies; GSK names new chairman.

FDA Social Media Guides Draw Industry, User Criticism

FDA Social Media Guides Draw Industry, User Criticism

Two FDA guidance documents on how health product manufacturers may participate in social media have each drawn criticism from affected industry and consumer groups.

Sanofi rolls out HCP software

Sanofi rolls out HCP software

MyStar Connect—available in Europe—translates glucose readings into actionable graphics.

Acorda's $525M Civitas buy opens Parkinson's pipeline

Acorda's $525M Civitas buy opens Parkinson's pipeline

The all-cash deal gives Acorda access to an experimental inhaled Parkinson's treatment that is meant to help patients when medication levels dip and symptoms surface.

NICE poised to turn down three ulcerative colitis drugs

Final guidance will float in around January, but the news puts Janssen and AbbVie on notice.

Advocates want FDA's Hamburg out

The reason: opioids.

Philips focuses on healthcare tech

Lightbulb company Royal Philips is swapping its heritage for the consumer healthcare business.

Five things for pharma marketers to know: Wednesday, September 24

Five things for pharma marketers to know: Wednesday, September 24

Pfizer tries to acquire Actavis; PhRMA says FDA social media rules are bad for consumers; US diabetes rates begin to slow.

US Treasury takes action on tax inversions

US Treasury takes action on tax inversions

The Treasury announced Monday it would eliminate certain techniques companies use to facilitate so-called tax inversions, which a number of drug companies have undertaken in the past six months.

MedImmune gets Fast Track nod

The drugmaker says the Phase-I monoclonal antibody has three distinct mechanisms of action.

OIG: Crack down on Medicare co-pay cards

The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.

Five things for pharma marketers to know: Tuesday, September 23

Five things for pharma marketers to know: Tuesday, September 23

Treasury Department takes action against corporate tax inversions; CDC pegs Ebola worst case scenario at 1.4 million infected by new year; NIH allocates $10 million in grants to increase female clinical trials.

OPDP slams cholesterol drug's e-mail claims

OPDP slams cholesterol drug's e-mail claims

The Office of Prescription Drug Promotion took aim at Cipher Pharmaceuticals and its marketer Kowa, in an Untitled Letter over an e-mail alert making what it said were unsubstantiated assertions.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Auxilium turns down Endo, leaves door open

Auxilium turns down Endo, leaves door open

The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.

Five things for pharma marketers to know: Monday, September 22

Five things for pharma marketers to know: Monday, September 22

GSK releases polio-infected water into Lasne River in Belgium; House reps Burgess and Schwartz introduce CME exemption bill for Sunshine Act; NIH and FDA announce plan to create facebook-esque catalogue of oral-drugs.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

Why Pharma Should Stop Marketing Products and Start Marketing Services

Why Pharma Should Stop Marketing Products and Start Marketing Services

Today, we're all still trying to get people to buy our drugs and be a trusted health advisor, but these two goals seem to be working firmly against each other.

FDA panel votes against taking drugs for "low-T"

FDA panel votes against taking drugs for "low-T"

An FDA advisory panel voted overwhelmingly against the use of testosterone-replacement drugs for "low-T" Wednesday, saying the label should narrow and that more safety information is needed.

Merck's weekly DPP-IV on par with daily Januvia: study

Merck's weekly DPP-IV on par with daily Januvia: study

Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.

Five things for pharma marketers to know: Thursday, September 18

Five things for pharma marketers to know: Thursday, September 18

FDA panel votes overwhelmingly against Low-T drugs; Stenda approved for fast-acting ED treatment; and Bayer hones life-sci focus, spins off material sciences business.

Rate of Sovaldi non-adherence points to need for patient support

Rate of Sovaldi non-adherence points to need for patient support

A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.

Endo makes $2.2B bid for Auxilium

Endo makes $2.2B bid for Auxilium

Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.

DOJ eyes Ranbaxy pricing

The Department of Justice is looking into Medicaid pricing.

Switzerland wants lower drug prices

Switzerland is pushing Roche to lower its prices on Perjeta

Five things for pharma marketers to know: Wednesday, September 17

HealthKit off to a bumpy start; Endo offers $2.2 billion for Auxilium; Gilead advanced pancreatic cancer drug fails in trial.

BMS striving to push Opdivo past Keytruda

BMS striving to push Opdivo past Keytruda

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.

Merck osteoporosis drug does not wow

Merck osteoporosis drug does not wow

Analysts do not expect odanacatib to be a major earner.

NY sues over Forest Alzheimer's medication

NY's attorney general alleges that a formulation switch is an attempt to create monopoly.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.